Search by Drug Name or NDC
NDC 68727-0900-03 Rylaze 20 mg/mL Details
Rylaze 20 mg/mL
Rylaze is a INTRAMUSCULAR INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is ASPARAGINASE.
MedlinePlus Drug Summary
Asparaginase erwinia chrysanthemi (recombinant)-rywn injection is used with other chemotherapy medications to treat acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells) and to treat a type of non-Hodgkins lymphoma (NHL: cancer that begins in a type of white blood cell that normally fights infection) in adults and children 1 month of age and older. It is used in people who have had some types of allergic reactions to medications similar to asparaginase erwinia chrysanthemi (recombinant)-rywn such as asparaginase (Elspar). Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells.
Related Packages: 68727-0900-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Injection
Asparaginase erwinia chrysanthemi is used with other chemotherapy medications to treat acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells). It is used in patients who have had some types of allergic reactions to medications similar to asparaginase erwinia chrysanthemi such as (asparaginase [Elspar] or pegaspargase [Oncaspar]). Asparaginase erwinia chrysanthemi is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells.
Related Packages: 68727-0900-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Asparaginase Erwinia Chrysanthemi Injection
Product Information
| NDC | 68727-0900 |
|---|---|
| Product ID | 68727-900_19a01d9d-35ce-49dc-a2c9-958a1db5f895 |
| Associated GPIs | 21250010602020 |
| GCN Sequence Number | 082476 |
| GCN Sequence Number Description | asparaginase Erwinia-rywn VIAL 10MG/0.5ML INTRAMUSC |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 49911 |
| HICL Sequence Number | 047474 |
| HICL Sequence Number Description | ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN |
| Brand/Generic | Brand |
| Proprietary Name | Rylaze |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | asparaginase erwinia chrysanthemi (recombinant)-rywn |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/mL |
| Substance Name | ASPARAGINASE |
| Labeler Name | Jazz Pharmaceuticals, Inc. |
| Pharmaceutical Class | Asparaginase [CS], Asparagine-specific Enzyme [EPC] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761179 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 68727-0900-03 (68727090003)
| NDC Package Code | 68727-900-03 |
|---|---|
| Billing NDC | 68727090003 |
| Package | 3 VIAL, SINGLE-DOSE in 1 CARTON (68727-900-03) / .5 mL in 1 VIAL, SINGLE-DOSE (68727-900-01) |
| Marketing Start Date | 2021-06-30 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |